Difficulty: Medium
Average Score: 90%
Practice
A monoclonal antibody called '3F8' was developed to treat neuroblastoma and was subsequently improved by:
Correct answer
D
Rationale
The correct answer is D. By engineering a form of the antibody with human variable region protein sequences (choice B), it reduces the risk of immune response in patients. Similarly, by engineering a form with human constant region protein sequences (choice C), it further reduces immunogenicity. Therefore, both B and C contribute to making the antibody more suitable for human use, enhancing its efficacy and safety in treating neuroblastoma. Choices A and D are incorrect as they do not address the crucial aspect of reducing immunogenicity through humanization of the antibody.